Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...
iaea.org

Central Nervous System Radiotracer Development: Bench to Bedside

This publication provides an overview of central nervous system (CNS) radiotracer development, discussing different aspects and stages of development. Non-invasive neuroimaging with radiotracers can ...
The Manila Times

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the ...